Printer Friendly

Decreased levels of serum zonulin and copeptin in chronic Hepatitis-B patients.

Byline: Mustafa Kerem Calgin and Yeliz Cetinkol

KEYWORDS: Chronic Hepatitis B, Zonulin, Copeptin, Hepatitis Diagnosis.

INTRODUCTION

Hepatitis B virus (HBV) infection is a significant global health problem causing chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC). The World Health Organization estimates that more than 350 million people are chronic HBV carriers.1 In people with this infection, monitoring the progression of the disease, treatment of chronic hepatitis and early diagnosis of linked diseases that may develop has a clinically important role. A variety of diagnostic tests have been developed to identify HBV infection. Serum viral load level is the most important marker used to begin antiviral treatment and assess treatment efficacy.2,3 Additionally, it is important to develop cheaper and more accessible methods for diagnosis and monitoring of chronic hepatitis B (CHB) infections. The liver and intestine are anatomically and physiologically linked organs. The liver is linked to the small intestine through the bile duct and bile created in the liver is carried to the intestine in this way.

Additionally, nearly all blood from the stomach and intestines passes through the liver. The human intestine hosts various species of bacterial assemblages called the intestine microbiota.4 Bacterial peptidoglycans, flagellins and other microbial metabolic by-products found in the intestines are known to worsen the clinical progression in patients with chronic liver diseases. Intestinal bacteria may penetrate the intestinal mucosa in cirrhosis patients by different mechanisms; however, the precondition for this is damage to the intestinal barrier causing increased mucosal permeability.5 The intestinal barrier is provided by the intercellular "tight junctions (TJs)" between intestinal mucosa cells. Faced with high resistance of enterocyte plasma membranes, dissolved material flow is via the paracellular route and TJs are the basic obstacle to this route.

Previously TJs were considered to be static, but they are highly dynamic structures and there is evidence that they adapt to developmental, physiological and pathologic situations.6 In recent years, the physiologic modulators of TJs have been discovered. Zonulin is the only human protein regulating modulation of intercellular TJs and intestinal permeability known to date. Zonulin binds to receptors activating some intracellular pathways and as a result TJs are opened and permeability increases.7,8 To keep arterial blood pressure within normal limits for cirrhosis patients, clear activation forms in endogenous vasoconstrictor systems like the renin - angiotensin - aldosterone system, sympathetic nervous system and vasopressin (AVP).9 Copeptin, a 39 - amino acid glycopeptide, biochemically is released from the neurohypophysis within pioneer preprovasopressin together with AVP. Contrary to AVP, copeptin is a very stable and easy to measure, non-functional peptide.

As a result, measurement of copeptin levels as a biomarker allowed the possibility of researching the role of AVP in clinical applications.10,11 Studies to date have shown that copeptin is not limited to its role in posterior hypophysis function, but simultaneously is a marker of systemic circulation disorder in liver diseases and is associated with prognosis.12,13 Zonulin and copeptin molecules have not been researched in HBV hepatitis to date. In this study, the serum zonulin and copeptin levels were measured in patients with diagnosis of CHB with the aim of easing antiviral treatment management in clinical applications and to investigate the association with viral load.

METHODS

Serum from 30 CHB patients was included in the assessment with measurement of viral load in the molecular microbiology laboratory. Control serum was obtained from 17 clinic patients with no known history of chronic disease, no intestinal disease and negative for serum HBsAg, anti - HBs and anti - HCV titers. Serum was stored at - 40AdegC until analysis. The study received permission from Ordu University clinical research ethics committee (2017/95).

Real - Time PCRs: Quantitative HBV - DNA real - time PCR tests were completed using a COBAS AmpliPrep/COBAS Taqman 48 system (Roche, Branchburg, NJ, USA). Viral nucleic acids were extracted from 500 ul patient serum with a COBAS AmpliPrep automated extractor according to the manufacturer's instructions. The measurement interval of the kit for HBV-DNA is 20 - 1.7 x 108 IU/ml.

ELISA: Serum copeptin measurements were completed with a Human Copeptin ELISA kit (Sunred Biological TechnologyA(r), Shanghai, People's Republic of China) and serum zonulin measurements used a Human Zonulin ELISA kit (Sunred Biological TechnologyA(r), Shanghai, People's Republic of China) according to the manufacturer's instructions. Plates were read with a Synergy HT microplate reader (BiotekA(r), Winooski, VT, USA).

Statistical Analysis: Normal distribution of data was checked with the Kolmogorov - Smirnov test, while homogeneity of group variance was checked with the Levene test. Variables abiding by assumptions were compared using the student T test for two groups and with the one - way ANOVA for more than two groups. Variables not abiding by assumptions were compared using the Mann - Whitney U test for two groups and the Kruskal - Wallis test for more than two groups. After the Kruskal - Wallis test, differing groups were determined with the Dunn test and results are represented by letters. Level of significance ([alpha]) for calculations and interpretation of results was taken as 5%. All statistical calculations were completed with the Statistical Package for the Social Sciences software 25.0 (IBM SPSS Statistics for Windows, Version 25.0. Chicago, IL: IBM Corp.).

Table-I: Study groups.

###CHB(n=30)

###HBV-DNA levels(IU/ml)###Control(n=17)

Subgroup 1###0-1x102(n=10)###-

Subgroup 2###1x103-1x105(n=10)###-

Subgroup 3###1x106-1x108(n=10)###-

Table-II: Characteristics of chronic hepatitis B patients and control group

###CHB(n=30)###Control(n=17)###p value

Age(Mean+-SD)###47.2+-13.9###57.1+-23.2###0.073NS

Zonulin###3.8(4.5)###12.7(2.6)###0.000***

(Median(IQR))

Copeptin###1.08(1.04)###3.7(0.8)###0.000***

(Median(IQR))

Table-III: Characteristics of chronic hepatitis B subgroups

###Subgroup1###Subgroup2###Subgroup3###p value

###n=10###n=10###n=10

Age###51.2+-13.7###40.3+-13.6###50.2+-12.7###0.159NS

(Mean+-SD)

Zonulin###5.3(5.2)A###4.7(4.4)AB###1.6(3.1)B###0.042*

(Median(IQR))

Copeptin###1.4(1.4)###1.1(0.9)###0.6(0.9)###0.170NS

(Median(IQR))

Table-IV: Correlation coefficients between subgroups, zonulin and copeptin.

###Zonulin###Copeptin

Subgroup###r###-0.510###-0.415

###p-value###0.004*###0.023**

RESULTS

The study included a total of 47 serum samples (20 female, 27 male). Those with gastrointestinal disease and chronic disease other than hepatitis were excluded from the study. Serum was classified in two main groups; CHB (n = 30) and control group (n = 17). Serum from the CHB group was divided into three subgroups according to contained viral nucleic acid amounts (Table-I).

Statistical results for CHB and control group: Student t test results for age found no statistically significant difference between the groups (p > 0.05). Mann - Whitney U test performed for zonulin and copeptin found the CHB group had statistically significantly lower values compared to the control group (p 0.05). Kruskal - Wallis test results for zonulin found the difference between subgroups was statistically significant (p < 0.05). The Dunn multiple comparison test performed with the aim of determining the differing groups found a statistically significant difference between subgroup one and subgroup three (p 0.05). Kruskal - Wallis test results for copeptin found no statistically significant difference between the groups (p > 0.05) (Table-III). The Spearman coefficients calculated with the aim of determining the correlation between the DNA amounts and serum zonulin and copeptin amounts in the subgroups are given in Table-IV.

The correlation coefficient between subgroup DNA amounts and serum zonulin levels was calculated as -0.510 and was statistically significant (p < 0.01). As serum DNA amounts increased, there was a reduction in zonulin amounts. The correlation coefficient for subgroup DNA amounts with serum copeptin levels was calculated as -0.415 and was found to be statistically significant (p 1 x 105 copies/mL) increases the risk of mortality and HCC associated with the liver.24 Some studies have shown that low viremia (serum HBV - DNA a$?1 x105 copies/mL) may cause liver cirrhosis and carries increased risk of HCC development.22 Though serum HBV - DNA concentration is not a definite marker for CHB, it may be used to predict the development of liver disease. In our study, patients with low serum HBV - DNA load (subgroup 1) had high zonulin amounts, showing intestinal permeability increased in patients with low viral loads.

The elevation in copeptin amounts identified in the same patients shows simultaneous disruption of systemic circulation. Our findings support the opinion that risk of cirrhosis and HCC development may increase for CHB patients with low viremia.

CONCLUSION

The negative correlation of serum zonulin and copeptin molecules with HBV - DNA load revealed in our study shows that the biomolecules of zonulin and copeptin may be used for treatment monitoring in these patients. These results may allow the development of new approaches to diagnosis and monitoring of HBV infections. Additionally, the relationships between zonulin and copeptin metabolism and chronic viral hepatitis infections is very complicated. To support these results, there is a need for more comprehensive studies with the aim of assessing long term effects on patients, and understanding the relationships between viral load with intestinal permeability and systemic circulation disorders in chronic viral hepatitis patients.

Grant Support and Financial Disclosures: This study was supported by Ordu University Scientific Research Projects Coordination Unit with project number HD-1717.

REFERENCES

1. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23(4):512-520. doi: 10.1111/j.1440-1746.2008.05384.x.

2. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003;37(6):1309-1319. doi: 10.1053/jhep.2003.50208.

3. Wang J, Dong A, Liu G, Anderson GJ, Hu TY, Shi J, et al. Correlation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assay. Sci Rep. 2016;6(1):34252. doi: 10.1038/srep34252.

4. Kang Y, Cai Y. Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy. J Hosp Infect. 2017;96(4):342-348. doi: 10.1016/j.jhin.2017.04.007.

5. Palma P, Mihaljevic N, Hasenberg T, Keese, M, Koeppel TA. Intestinal barrier dysfunction in developing liver cirrhosis: An in vivo analysis of bacterial translocation. Hepatol Res. 2007;37(1):6-12. doi: 10.1111/j.1872-034X.2007.00004.x.

6. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91(1):151-175. doi: 10.1152/physrev.00003.2008.

7. Fasano A. Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications. Clin Gastroenterol Hepatol. 2012;10(10):1096-1100. doi: 10.1016/j.cgh.2012.08.012.

8. Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzel-Arnett S, Buzza MS, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA. 2009;106(39):16799-16804. doi: 10.1073/pnas.0906773106.

9. Sola E, Kerbert AJ, Verspaget HW, Moreira R, Pose E, Ruiz P, et al. Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. J Hepatol. 2016;65(5):914-920. doi: 10.1016/j.jhep.2016.07.003.

10. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112-119. doi: 10.1373/clinchem.2005.060038.

11. Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008;19(2):43-49. doi: 10.1016/j.tem.2007.11.001.

12. Claria J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatol. 2016;64(4):1249-1264. doi: 10.1002/hep.28740.

13. Lewandowski KC, Brabant G. Potential Clinical Utility of Copeptin (C-terminal provasopressin) measurements in clinical medicine. Exp Clin Endocrinol Diabetes. 2016;124(3):173-177. doi: 10.1055/s-0035-1569341.

14. Esnafoglu E, Cirrik S, Ayyildiz SN, Erdil A, Erturk EY, Dagli A, et al. Increased Serum Zonulin Levels as an Intestinal Permeability Marker in Autistic Subjects. J Pediatr. 2017;188:240-244. doi: 10.1016/j.jpeds.2017.04.004.

15. Klaus DA, Motal MC, Burger-Klepp U, Marschalek C, Schmidt EM, Lebherz-Eichinger D, et al. Increased plasma zonulin in patients with sepsis. Biochem Med (Zagreb). 2013;23(1):107-111. doi: 10.11613/BM.2013.013.

16. Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Bodzenta-Lukaszyk A, Malyszko J. Zonulin, inflammation and iron status in patients with early stages of chronic kidney disease. Int Urol Nephrol. 2018;50(1):121-125. doi: 10.1007/s11255-017-1741-5.

17. Boullier S, Tanguy M, Kadaoui KA, Caubet C, Sansonetti P, Corthesy B, et al. Secretory IgA-mediated neutralization of Shigella flexneri prevents intestinal tissue destruction by down-regulating inflammatory circuits. J Immunol. 2009;183(9):5879-5885. doi: 10.4049/jimmunol.0901838.

18. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003;361(9356):512-519. doi: 10.1016/S0140-6736(03)12489-0.

19. Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol. 2011;61(3):693-703. doi: 10.1007/s00248-010-9801-8.

20. El Asmar R, Panigrahi P, Bamford P, Berti I, Not T, Coppa GV, et al. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology. 2002;123(5):1607-1615. doi: 10.1053/gast.2002.36578.

21. Chou HH, Chien WH, Wu LL, Cheng CH, Chung CH, Horng JH, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc Natl Acad Sci USA. 2015;112(7):2175-2180. doi: 10.1073/pnas.1424775112.

22. Wursthorn K, Manns MP, Wedemeyer H. Natural history: the importance of viral load, liver damage and HCC. Best Pract Res Clin Gastroenterol. 2008;22(6):1063-1079. doi: 10.1016/j.bpg.2008.11.006.

23. Xu QH, Shu X, Chen LB, Huang HH, Zhang K, Li G. [Relationships between liver function test, serum HBeAg or HBV DNA level and liver pathological changes in patients with chronic hepatitis B]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2008;22(6):422-424.

24. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101(8):1797-1803. doi: 10.1111/j.1572-0241.2006.00647.x.
COPYRIGHT 2019 Knowledge Bylanes
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Pakistan Journal of Medical Sciences
Date:Jun 30, 2019
Words:2637
Previous Article:Healthcare needs of the Muslim patient community in the undergraduate medical curriculum - Are we there?
Next Article:The relationship of 1,25-dihydroxyvitamin D and Vitamin D binding protein in periodontitis.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |